




Instance: composition-en-682a1ddf5b561c3896c1e826a81d2aed
InstanceOf: CompositionUvEpi
Title: "Composition for sevelamer Package Leaflet"
Description:  "Composition for sevelamer Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp2ab208eb9cef3ae74ba62338b09d536d)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sevelamer"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Sevelamer carbonate Winthrop is and what it is used for </li>
<li>What you need to know before you take Sevelamer carbonate Winthrop </li>
<li>How to take Sevelamer carbonate Winthrop </li>
<li>Possible side effects </li>
<li>How to store Sevelamer carbonate Winthrop </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sevelamer is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sevelamer is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sevelamer carbonate Winthrop contains the active substance sevelamer carbonate. It binds phosphate from 
food in the digestive tract and so reduces serum phosphorus levels in the blood. </p>
<p>This medicine is used to control hyperphosphataemia (high blood phosphate levels) in: 
* adult patients on dialysis (a blood clearance technique). It can be used in patients undergoing 
haemodialysis (using a blood filtration machine) or peritoneal dialysis (where fluid is pumped into the 
abdomen and an internal body membrane filters the blood); 
* patients with chronic (long-term) kidney disease who are not on dialysis and have a serum (blood) 
phosphorus level equal to or above 1.78 mmol/L.  </p>
<p>This medicine should be used with other treatments such as calcium supplements and vitamin D to prevent 
the development of bone disease. </p>
<p>Increased levels of serum phosphorus can lead to hard deposits in your body called calcification. These 
deposits can stiffen your blood vessels and make it harder for blood to be pumped around the body. 
Increased serum phosphorus can also lead to itchy skin, red eyes, bone pain and fractures. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sevelamer"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sevelamer"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Sevelamer carbonate Winthrop:<br />
* if you are allergic to sevelamer carbonate or any of the other ingredients of this medicine (listed in 
section 6). 
* if you have low levels of phosphate in your blood (your doctor will check this for you). 
* if you have bowel obstruction.  </p>
<p>Warnings and precautions<br />
Talk to your doctor before taking Sevelamer carbonate Winthrop: 
* if you have swallowing problems. Your doctor can rather prescribe sevelamer carbonate powder for 
oral suspension. 
* if you have problems with motility (movement) in your stomach and bowel 
* if you have active inflammation of the bowel 
* if you have undergone major surgery on your stomach or bowel. </p>
<p>Talk to your doctor while taking Sevelamer carbonate Winthrop: 
* if you experience severe abdominal pain, stomach or intestine disorders, or blood in the stool 
(gastrointestinal bleeding). These symptoms can be due to serious inflammatory bowel disease caused 
by sevelamer crystal deposit in your bowel. Contact your doctor who will decide on continuing the 
treatment or not. </p>
<p>Additional treatments: 
Due to either your kidney condition or your dialysis treatment you may: 
* develop low or high levels of calcium in your blood. Since this medicine does not contain calcium 
your doctor might prescribe additional calcium tablets. 
* have a low amount of vitamin D in your blood. Therefore, your doctor may monitor the levels of 
vitamin D in your blood and prescribe additional vitamin D as necessary. If you do not take 
multivitamin supplements you may also develop low levels of vitamins A, E, K and folic acid in your 
blood and therefore your doctor may monitor these levels and prescribe supplemental vitamins as 
necessary. 
* have disturbed level of bicarbonate in your blood and increased acidity in the blood and other body 
tissue. Your doctor should monitor the level of bicarbonate in your blood. </p>
<p>Special note for patients on peritoneal dialysis: 
You may develop peritonitis (infection of your abdominal fluid) associated with your peritoneal dialysis. 
This risk can be reduced by careful adherence to sterile techniques during bag changes. You should tell your 
doctor immediately if you experience any new signs or symptoms of abdominal distress, abdominal swelling, 
abdominal pain, abdominal tenderness, or abdominal rigidity, constipation, fever, chills, nausea or vomiting.  </p>
<p>Children 
Do not give this medicine to children below the age of 6 years because the safety and efficacy in children 
(below the age of 6 years) have not been studied. </p>
<p>Other medicines and Sevelamer carbonate Winthrop 
Tell your doctor if you are taking, have recently taken or might take any other medicines. </p>
<ul>
<li>
<p>Sevelamer carbonate Winthrop should not be taken at the same time as ciprofloxacin (an antibiotic). </p>
</li>
<li>
<p>If you are taking medicines for heart rhythm problems or for epilepsy, you should consult your doctor 
when taking Sevelamer carbonate Winthrop. </p>
</li>
<li>
<p>The effects of medicines such as ciclosporin, mycophenolate mofetil and tacrolimus (medicines used 
to suppress the immune system) may be reduced by Sevelamer carbonate Winthrop. Your doctor will 
advise you if you are taking these medicines. </p>
</li>
<li>
<p>Thyroid hormone deficiency may uncommonly be observed in certain people taking levothyroxine 
(used to treat low thyroid hormone levels) and Sevelamer carbonate Winthrop. Therefore your doctor 
may monitor the levels of thyroid stimulating hormone in your blood more closely.  </p>
</li>
<li>
<p>Medicines treating heartburn and reflux from your stomach or oesophagus, such as omeprazole, 
pantoprazole, or lansoprazole, known as  proton pump inhibitors , may reduce the efficacy of 
Sevelamer carbonate Winthrop.  Your doctor may monitor the phosphate level in your blood. </p>
</li>
</ul>
<p>Your doctor will check for interactions between Sevelamer carbonate Winthrop and other medicines on a 
regular basis. </p>
<p>In some cases where Sevelamer carbonate Winthrop should be taken at the same time as another medicine, 
your doctor may advise you to take this medicine 1 hour before or 3 hours after Sevelamer carbonate 
Winthrop intake. Your doctor may also consider monitoring the levels of that medicine in your blood. 
Pregnancy and breast-feeding 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your 
doctor for advice before taking this medicine.<br />
The potential risk of Sevelamer carbonate Winthrop during human pregnancy is unknown. Talk to your 
doctor who will decide if you can continue the treatment with Sevelamer carbonate Winthrop. </p>
<p>It is unknown whether Sevelamer carbonate Winthrop is excreted in breast milk and may affect your baby. 
Talk to your doctor who will decide if you can breastfeed your baby or not, and if it is necessary to stop 
Sevelamer carbonate Winthrop treatment. </p>
<p>Driving and using machines 
Sevelamer carbonate Winthrop is unlikely to affect your ability to drive or to use machines.  </p>
<p>Excipients 
This medicine contains less than 1 mmol sodium (23 mg) per tablet that is to say essentially  sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sevelamer"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sevelamer"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. He will base the dose on your serum 
phosphorus level.  </p>
<p>The recommended starting dose of this medicine for adults and elderly is one to two tablets of 800 mg with 
each meal, 3 times a day. Check with your doctor, pharmacist or nurse if you are not sure. </p>
<p>Take Sevelamer carbonate Winthrop after your meal or with food. </p>
<p>The tablets must be swallowed whole. Do not crush, chew or break into pieces. </p>
<p>Initially, your doctor will check the levels of phosphorus in your blood every 2-4 weeks and may adjust the 
dose of Sevelamer carbonate Winthrop when necessary to reach an adequate phosphate level.  </p>
<p>Follow the diet prescribed by your doctor. </p>
<p>If you take more Sevelamer carbonate Winthrop than you should 
In the event of a possible overdose you should contact your doctor immediately. </p>
<p>If you forget to take Sevelamer carbonate Winthrop 
If you have missed one dose, this dose should be omitted and the next dose should be taken at the usual time 
with a meal. Do not take a double dose to make up for a forgotten dose. </p>
<p>If you stop taking Sevelamer carbonate Winthrop 
Taking your Sevelamer carbonate Winthrop treatment is important to maintain an appropriate phosphate level 
in your blood. Stopping Sevelamer carbonate Winthrop would lead to important consequences such as 
calcification in the blood vessels. If you consider stopping your Sevelamer carbonate Winthrop treatment, 
contact your doctor or pharmacist first. 
If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Constipation is a very common side effect. It can be an early symptom of a blockage in your intestine. In 
case of constipation, please inform your doctor or pharmacist if you experience it. </p>
<p>Some side effects could be serious. If you get any of the following side effects, seek immediate medical 
attention:</p>
<ul>
<li>Allergic reaction (signs including rash, hives, swelling, trouble breathing). This is a very rare side effect (may 
affect up to 1 in 10,000 people). </li>
<li>Blockage in the intestine (signs include: severe bloating; abdominal pain, swelling or cramps; severe 
constipation) has been reported. Frequency is not known. </li>
<li>Rupture in the intestinal wall (signs include: severe stomach pain, chills, fever, nausea, vomiting, or a 
tender abdomen) has been reported. Frequency is not known. </li>
<li>Serious inflammation of the large bowel (symptoms include: severe abdominal pain, stomach or intestine 
disorders, or blood in the stool [gastrointestinal bleeding]) and crystal deposit in the intestine have been 
reported. Frequency is not known. </li>
</ul>
<p>Other side effects have been reported in patients taking Sevelamer carbonate Winthrop:  </p>
<p>Very common (may affect more than 1 in 10 people): 
* vomiting,<br />
* upper abdominal pain, 
* nausea. </p>
<p>Common (may affect up to 1 in 10 people): 
* diarrhoea,<br />
<em> stomach ache, 
* indigestion,<br />
</em> flatulence. </p>
<p>Not known (frequency cannot be estimated from the available data): 
* cases of itching, 
* rash,<br />
* slow intestine motility (movement). </p>
<p>Reporting of side effects<br />
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. 
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting 
side effects, you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sevelamer"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sevelamer"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date stated on the bottle and/or carton after  EXP . The expiry date 
refers to the last day of that month. </p>
<p>Keep the bottle container tightly closed in order to protect from moisture.<br />
This medicine does not require any special temperature storage conditions.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw 
away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Sevelamer carbonate Winthrop contains </p>
<ul>
<li>The active substance is sevelamer carbonate. Each film-coated tablet contains 800 mg of sevelamer 
carbonate. </li>
<li>The other ingredients are microcrystalline cellulose, sodium chloride, zinc stearate, hypromellose (E464), 
diacetylated monoglycerides. </li>
</ul>
<p>What Sevelamer carbonate Winthrop looks like and contents of the pack </p>
<p>Sevelamer carbonate Winthrop film-coated tablets are white to off-white oval tablets with RV800 engraved 
on one side. The tablets are packed in high density polyethylene bottles with a child-resistant polypropylene 
closure and an induction seal. </p>
<p>Pack sizes:<br />
Each bottle contains 30 tablets or 180 tablets. 
Packs of 1 bottle of 30 tablets or 180 tablets with no outer carton 
Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Sanofi B.V. 
Paasheuvelweg 1105 BP Amsterdam 
The Netherlands </p>
<p>Manufacturer 
Genzyme Ireland Limited 
IDA Industrial Park 
Old Kilmeaden Road 
Waterford 
Ireland </p>
<p>Sanofi Winthrop Industrie 
1 rue de la Vierge 
Ambares et Lagrave 
33565 Carbon Blanc cedex 
France </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder. </p>
<p>Belgi /Belgique/Belgien/ 
Luxembourg/Luxemburg 
Sanofi Belgium 
T l/Tel: + 32 2 710 54 Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91 <br />
Swixx Biopharma EOOD 
 .: +359 (0)2 4942 Magyarorsz g 
SANOFI-AVENTIS Zrt 
Tel: +36 1 505 0 esk  republika 
sanofi-aventis, s.r.o. 
Tel: +420 233 086 Malta 
Sanofi S.r.l. 
Tel: +39 02 39394Danmark<br />
Sanofi A/S 
Tlf: +45 45 16 70 Nederland 
Sanofi B.V.<br />
Tel: +31 20 245 4Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21 Norge 
sanofi-aventis Norge AS 
Tlf: + 47 67 10 71 Eesti 
Swixx Biopharma O <br />
Tel: +372 640 10  sterreich 
sanofi-aventis GmbH 
Tel: + 43 1 80 185 - 0 </p>
<p>Sanofi-Aventis   AEBE 
 : +30 210 900 1Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00 Espa a 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 Portugal 
Sanofi   Produtos Farmac uticos, Lda.. 
Tel: +351 21 35 89 France 
Sanofi Winthrop Industrie 
T l : 0 800 222 Appel depuis l tranger : +33 1 57 63 23 Rom nia 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078 Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 235 51 Ireland 
sanofi-aventis Ireland Ltd T/A SANOFI 
Tel: +353 (0) 1 4035 Slovensk  republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33  sland 
Vistor hf. 
S mi: +354 535 7Suomi/Finland 
Sanofi Oy 
Puh/Tel: + 358 201 200 Italia 
Sanofi S.r.l. 
Tel: 800 536 Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50 <br />
C.A. Papaellinas Ltd. 
 : +357 22 741Latvija 
Swixx Biopharma SIA<br />
Tel: +371 6 616 47 United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2This leaflet was last revised in  </p>
<p>Other sources of information  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-682a1ddf5b561c3896c1e826a81d2aed
InstanceOf: CompositionUvEpi
Title: "Composition for sevelamer Package Leaflet"
Description:  "Composition for sevelamer Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp2ab208eb9cef3ae74ba62338b09d536d)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - sevelamer"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Sevelamer carbonate Winthrop<br />
3. Sådan skal du tage Sevelamer carbonate Winthrop<br />
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What sevelamer is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What sevelamer is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Det aktive stof i Sevelamer carbonate Winthrop er sevelamercarbonat. Det binder fosfat fra maden i 
fordøjelseskanalen og nedsætter på denne måde fosfat niveauet i blodet. </p>
<p>Dette lægemiddel anvendes til kontrol af hyperfosfatæmi (forhøjet fosfat niveauer) hos: 
 
voksne patienter i dialyse (en blodrensningsteknik). Det kan anvendes til patienter i hæmodialyse (ved 
hjælp af en blodfiltreringsmaskine) eller peritonealdialyse (hvor væske pumpes ind i bughulen og en 
indre membran i kroppen filtrerer blodet); 
 
patienter med kronisk (langvarig) nyresygdom, som ikke er i dialyse, og har en serum (blod) fosfat 
niveau lig med eller over 1,78 mmol/l. </p>
<p>Dette lægemiddel bør anvendes med andre behandlinger såsom calciumtilskud og D-vitamin for at forhindre 
udviklingen af knoglesygdom. 
Et øget indhold af serumfosfat kan føre til hårde aflejringer i din krop, kaldet forkalkning. Aflejringerne kan 
gøre dine blodkar stive og gøre det mere besværligt for blodet at blive pumpet rundt i kroppen. Et øget 
niveau af fosfat i blodet kan også medføre hudkløe, røde øjne og smerter i knogler eller knoglebrud. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take sevelamer"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take sevelamer"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Sevelamer carbonate Winthrop<br />
 
hvis du er allergisk over for sevelamercarbonate eller et af de øvrige indholdsstoffer (angivet i punkt 
6). 
 
hvis du har et lavt indhold af fosfat i blodet (lægen måler dette) 
 
hvis du har tilstoppede tarme<br />
 </p>
<p>Advarsler og forsigtighedsregler 
Tal med lægen før du tager Sevelamer carbonate Winthrop: 
 
hvis du har problemer med at synke. Din læge kan ordinere sevelamarcarbonate pulver til oral 
suspension 
 
hvis du har problemer med motiliteten (bevægeligheden) i maven og tarmene 
 
hvis du har aktiv betændelse i tarmen 
 
hvis du har fået en større operation i maven eller tarmene </p>
<p>Tal med din læge, mens du tager Sevelamar carbonate Winthrop: 
•<br />
hvis du oplever svære mavesmerter, mave eller tarmsygdomme, eller blod i afføringen 
(gastrointestinal blødning). Disse symptomer kan skyldes alvorlig inflammatorisk tarmsygdom 
grundet opbygning af sevelamerkrystaller i tarmen. Kontakt din læge, der vil beslutte om 
behandlingen skal fortsættes eller ej. </p>
<p>Øvrige behandlinger: 
På grund af enten din nyresygdom eller din dialysebehandling kan følgende gælde for dig: 
 
Du kan få enten et højt eller lavt indhold af kalk i blodet. Eftersom dette lægemiddel ikke indeholder 
kalk, kan lægen ordinere et kalktilskud i form af tabletter. 
 
Du kan have for lidt D-vitamin i blodet. Lægen vil derfor måle indholdet af D-vitamin i dit blod og 
udskrive et D-vitamintilskud, hvis det er nødvendigt. Hvis du ikke tager multivitaminer, kan indholdet 
af A-, E- og K-vitamin samt folinsyre i dit blod blive for lavt. Lægen vil derfor eventuelt måle 
indholdet af disse vitaminer og ordinere vitamintilskud, hvis det er nødvendigt. 
 
Der har forstyrret indhold af bikarbonat i blodet, og øget surhedsgrad i blodet og andre kropsvæv. Din 
læge bør overvåge indholdet af bikarbonat i dit blod. </p>
<p>Patienter i peritonealdialyse: 
Du kan  udvikle bughindebetændelse (peritonitis) i forbindelse med peritonealdialysen. Risikoen herfor kan 
reduceres ved nøje at følge anvisningerne, når poserne udskiftes. Tal straks med lægen, hvis du oplever nye 
tegn eller symptomer på mavebesvær, oppustet mave, mavesmerter, ømhed i maven, stivhed i maven, 
forstoppelse, feber, kulderystninger, kvalme eller opkastning.  </p>
<p>Børn 
Giv ikke dette lægemiddel til børn under 6 år, da sikkerheden og virkningen hos børn (under 6 år) ikke er 
undersøgt. </p>
<p>Brug af anden medicin sammen med Sevelamer carbonate Winthrop 
Fortæl det altid til lægen, hvis du tager anden medicin eller har gjort det for nylig. </p>
<p> 
Sevelamer carbonate Winthrop må ikke tages på samme tid som ciprofloxacin (antibiotikum). </p>
<p> 
Hvis du tager medicin for problemer med hjerterytmen eller for epilepsi, skal du fortælle det til lægen, 
inden du tager Sevelamer carbonate Winthrop. </p>
<p> 
Virkningen af medicin såsom ciclosporin, mycophenolatmofetil og tacrolimus (medicin der anvendes 
til at hæmme immunsystemet) kan blive reduceret af Sevelamer carbonate Winthrop. Lægen vil 
rådgive dig, hvis du tager disse lægemidler. </p>
<p> 
Underskud af stofskifthormoner ses i sjældne tilfælde hos visse personer, der tager levothyroxin 
(bruges til at behandle lavt indhold af tyreoideahormon) og Sevelamer carbonate Winthrop. Derfor vil 
lægen nøje måle indholdet af tyreoidea-stimulerende hormon i dit blod.  </p>
<p> 
Medicin til behandling af halsbrand og reflux fra din mave eller spiserør, såsom omeprazol, 
pantoprazol eller lansoprazol, kendt som "protonpumpehæmmere", kan nedsætte Sevelamer carbonate 
Winthrops virkning. Din læge kan måle fosfatniveauet i dit blod. </p>
<p>Lægen vil jævnligt kontrollere vekselvirkningen mellem Sevelamer carbonate Winthrop og eventuel anden 
medicin. </p>
<p>I nogle tilfælde, hvor Sevelamer carbonate Winthrop tages sammen med anden medicin, vil lægen rådgiver 
dig, hvis du skal tage den anden medicin 1 time før eller 3 timer efter, at du har taget Sevelamer carbonate 
Winthrop. Lægen kan også måle indholdet af den anden medicin i dit blod. </p>
<p>Graviditet og amning<br />
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du 
spørge din læge til råds, før du tager dette lægemiddel.  </p>
<p>Den mulige risiko ved at tage Sevelamer carbonate Winthrop under graviditet er ukendt. Tal med din læge, 
som vil afgøre, om du kan fortsætte behandlingen med Sevelamer carbonate Winthrop. </p>
<p>Det vides ikke om Sevelamer carbonate Winthrop udskilles i modermælken, og kan påvirke din baby. Tal 
med din læge, som vil beslutte, om du kan amme din baby eller ej, og om det er nødvendigt at stoppe 
behandling med Sevelamer carbonate Winthrop. </p>
<p>Trafik- og arbejdssikkerhed 
Det er usandsynligt, at Sevelamer carbonate Winthrop påvirker din evne til at køre eller betjene maskiner. </p>
<p>Hjælpestoffer 
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium per tablet, dvs. det er i det væsentlige 
"natriumfrit". </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take sevelamer"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take sevelamer"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid Sevelamer carbonate Winthrop nøjagtigt efter lægens anvisning. Lægen fastsætter doseringen ud 
fra indholdet af fosfat i dit blod.  </p>
<p>Den anbefalede startdosis af dette lægemiddel for voksne ældre er en til to tabletter af 800 mg sammen med 
hvert hovedmåltid 3 gange dagligt. Spørg lægen, apotekspersonalet eller sundhedspersonalet, hvis der er 
noget, du er i tvivl om. </p>
<p>Tag Sevelamer carbonate Winthrop efter eller sammen med din mad.  </p>
<p>Tabletterne skal synkes hele. De må ikke knuses, tygges eller brækkes i stykker. </p>
<p>I starten vil lægen måle indholdet af fosfat i dit blod hver 2.-4.uge og ændrer om nødvendigt doseringen af 
Sevelamer carbonate Winthrop, så indholdet af fosfat kommer til at ligge på et passende niveau. </p>
<p>Følg den diæt, din læge har ordineret. </p>
<p>Hvis du har taget for meget Sevelamer carbonate Winthrop<br />
Hvis du tror, at du har taget for meget, skal du straks kontakte lægen. </p>
<p>Hvis du har glemt at tage Sevelamer carbonate Winthrop<br />
Hvis du har glemt en dosis, skal du springe den over og tage næste dosis til sædvanlig tid sammen med et 
måltid. Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p>
<p>Hvis du holder op med at tage Sevelamer carbonate Winthrop 
Det er vigtigt, at du tager Sevelamer carbonate Winthrop, for at opretholde et passende fosfatindhold i dit 
blod. Hvis du holder op med at tage Sevelamer carbonate Winthrop kan det medføre alvorlige konsekvenser 
som forkalkning i blodkarrene. Hvis du overvejer at stoppe din Sevelamer carbonate Winthrop-behandling, 
skal du først kontakte din læge eller apotekspersonalet. 
Spørg lægen eller apoteketspersonalet, hvis du har yderligere spørgsmål om brugen af dette lægemiddel.  </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som al anden medicin give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Forstoppelse er en meget almindelig bivirkning. Det kan være et tidligt symptom på tilstopning af tarmene.  I 
tilfælde af forstoppelse, skal du fortælle det til lægen eller apotekspersonalet.  </p>
<p>Nogle bivirkninger kan være alvorlige. Hvis du får nogen af de følgende bivirkninger, skal du omgående 
søge lægehjælp:</p>
<ul>
<li>Allergisk reaktion (symptomer omfatter udslæt, nældefeber, hævelse, vejrtrækningsproblemer). Dette er en 
meget sjælden bivirkning (kan påvirke op til 1 ud af 10.000 personer). </li>
<li>Tilstopning af tarmene er blevet rapporteret (symptomer omfatter alvorlig oppustethed, mavesmerter, 
hævelse eller kramper, alvorlig forstoppelse). Frekvensen er ikke kendt.  </li>
<li>Perforering af tarmvæggen er blevet rapporteret (symptomer omfatter alvorlige mavesmerter, 
kulderystelser, feber, kvalme, opkastning, eller ømhed i maven). Frekvens er ikke kendt. </li>
<li>Alvorlig betændelse i tyktarmen (symptomer omfatter; alvorlige mavesmerter, mave-eller tarmsygdomme 
eller blod i afføringen [gastrointestinal blødning] og krystalaflejring i tarmen er rapporteret. Frekvens er ikke 
kendt.  </li>
</ul>
<p>Andre bivirkninger er rapporteret hos patienter, der tager Sevelamer carbonate Winthrop:<br />
Meget almindelig (kan påvirke flere end 1 ud af 10 personer):<br />
 
Opkastning,<br />
 
øvre mavesmerter,<br />
 
kvalme. </p>
<p>Almindelig (kan påvirke op til 1 ud af 10 personer):<br />
 
Diarré,<br />
 
mavepine,<br />
 
fordøjelsesbesvær,<br />
 
luft i maven </p>
<p>Ikke kendt (kan ikke estimeres ud fra forhåndenværende data): 
 
kløe,<br />
 
hududslæt,<br />
 
nedsat tarmbevægelse (motilitet). </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, sygeplejerske eller apoteket. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om 
sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store sevelamer"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store sevelamer"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på pakningen efter Exp. Udløbsdatoen er den sidste dag i 
den nævnte måned. </p>
<p>Hold tabletbeholderen tæt tillukket for at beskytte mod fugt.<br />
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen. </p>
<p>Spørg på apoteket, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke smide 
medicinrester i afløbet, toilettet eller skraldespanden.  </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Sevelamer carbonate Winthrop indeholder:</p>
<ul>
<li>Aktivt stof: sevelamercarbonat. Hver filmovertrukket tablet indeholder 800 mg sevelamercarbonat. </li>
<li>Øvrige indholdsstoffer: mikrokrystallinsk cellulose, natriumchlorid og zinkstearat, hypromellose 
(E464), diacetyleret monoglycerid. </li>
</ul>
<p>Udseende og pakningsstørrelser </p>
<p>Sevelamer carbonate Winthrop filmovertrukne tabletter er hvide til råhvide, ovale og har RV800 præget på 
den ene side. Tabletterne er pakket i HDPE-tabletbeholdere med børnesikret polypropylenlåg og 
induktionsforsegling. </p>
<p>Pakningsstørrelser:<br />
Hver tabletbeholder indeholder 30 tabletter eller 180 tabletter 
Pakninger med 1 tabletbeholder med 30 tabletter eller 180 tabletter uden ydrekarton.  </p>
<p>Ikke alle pakningsstørrelser er nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen </p>
<p>Indehaver af markedsføringstilladelsen:<br />
Sanofi B.V. 
Paasheuvelweg 1105 BP Amsterdam 
Holland </p>
<p>Fremstiller<br />
Genzyme Ireland Limited 
IDA Industrial Park 
Old Kilmeaden Road 
Waterford 
Irland </p>
<p>Sanofi Winthrop Industrie 
1 rue de la Vierge 
Ambares et Lagrave 
33565 Carbon Blanc cedex 
Frankrig </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale repræsentant 
for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien/ 
Luxembourg/Luxemburg 
Sanofi Belgium 
Tél/Tel: + 32 2 710 54<br />
Lietuva 
Swixx Biopharma UAB 
Tel: +370 5 236 91<br />
България 
Swixx Biopharma EOOD 
Тел.: +359 (0)2 4942<br />
Magyarország 
SANOFI-AVENTIS Zrt 
Tel: +36 1 505 0Česká republika 
sanofi-aventis, s.r.o. 
Tel: +420 233 086<br />
Malta 
Sanofi S.r.l. 
Tel: +39 02 39394Danmark<br />
Sanofi A/S 
Tlf: +45 45 16 70<br />
Nederland 
Sanofi B.V. 
Tel: +31 20 245 4Deutschland 
Sanofi-Aventis Deutschland GmbH 
Tel: 0800 52 52 Tel. aus dem Ausland: +49 69 305 21<br />
Norge 
sanofi-aventis Norge AS 
Tlf: + 47 67 10 71<br />
Eesti 
Swixx Biopharma OÜ<br />
Tel: +372 640 10<br />
Österreich 
sanofi-aventis GmbH 
Tel: + 43 1 80 185 - 0 
Ελλάδα 
Sanofi-Aventis Μονοπρόσωπη AEBE 
Τηλ: +30 210 900 1Polska 
sanofi-aventis Sp. z o.o. 
Tel.: +48 22 280 00<br />
España 
sanofi-aventis, S.A. 
Tel: +34 93 485 94 <br />
Portugal 
Sanofi - Produtos Farmacêuticos, Lda. 
Tel: +351 21 35 89<br />
France 
Sanofi Winthrop Industrie 
Tél : 0 800 222 Appel depuis l’étranger : +33 1 57 63 23<br />
România 
Sanofi Romania SRL 
Tel: +40 (0) 21 317 31 36<br />
Hrvatska 
Swixx Biopharma d.o.o. 
Tel: +385 1 2078<br />
Slovenija 
Swixx Biopharma d.o.o.<br />
Tel: +386 1 235 51<br />
Ireland 
sanofi-aventis Ireland Ltd T/A SANOFI 
Tel: +353 (0) 1 4035 600  </p>
<p>Slovenská republika 
Swixx Biopharma s.r.o. 
Tel: +421 2 208 33<br />
Ísland 
Vistor hf. 
Sími: +354 535 7 
Suomi/Finland 
Sanofi Oy 
Puh/Tel: + 358 201 200<br />
Italia 
Sanofi S.r.l. 
Tel: 800 536 Sverige 
Sanofi AB 
Tel: +46 (0)8 634 50<br />
Κύπρος 
C.A. Papaellinas Ltd. 
Τηλ: +357 22 741 
United Kingdom (Northern Ireland) 
sanofi-aventis Ireland Ltd. T/A SANOFI 
Tel: +44 (0) 800 035 2 
Latvija<br />
Swixx Biopharma SIA<br />
Tel: +371 6 616 47  </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. 
Indlægsseddel: Information til brugeren </p>
<p>Sevelamer carbonate Winthrop 0,8 g pulver til oral suspension 
sevelamercarbonat </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den indeholder 
vigtige oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
- Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor være med at give medicinen til 
andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. 
- Kontakt lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som ikke er 
nævnt her. Se punkt 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-682a1ddf5b561c3896c1e826a81d2aed
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sevelamer Package Leaflet for language en"
Description: "ePI document Bundle for sevelamer Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-682a1ddf5b561c3896c1e826a81d2aed"
* entry[0].resource = composition-en-682a1ddf5b561c3896c1e826a81d2aed

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp682a1ddf5b561c3896c1e826a81d2aed"
* entry[=].resource = mp682a1ddf5b561c3896c1e826a81d2aed
                            
                    
Instance: bundlepackageleaflet-da-682a1ddf5b561c3896c1e826a81d2aed
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for sevelamer Package Leaflet for language da"
Description: "ePI document Bundle for sevelamer Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-682a1ddf5b561c3896c1e826a81d2aed"
* entry[0].resource = composition-da-682a1ddf5b561c3896c1e826a81d2aed

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp682a1ddf5b561c3896c1e826a81d2aed"
* entry[=].resource = mp682a1ddf5b561c3896c1e826a81d2aed
                            
                    



Instance: mp682a1ddf5b561c3896c1e826a81d2aed
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Sevelamer carbonate Winthrop 800 mg film-coated tablets"
Description: "Sevelamer carbonate Winthrop 800 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/14/952/001   180 film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Sevelamer carbonate Winthrop 800 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 682a1ddf5b561c3896c1e826a81d2aedListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "sevelamer"

* status = #current
* mode = #working

* title = "List of all ePIs associated with sevelamer"

* subject = Reference(mp2ab208eb9cef3ae74ba62338b09d536d)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#sevelamer "sevelamer"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-682a1ddf5b561c3896c1e826a81d2aed) // sevelamer en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-682a1ddf5b561c3896c1e826a81d2aed) // sevelamer da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-682a1ddf5b561c3896c1e826a81d2aed
InstanceOf: List

* insert 682a1ddf5b561c3896c1e826a81d2aedListRuleset
    